Brief · 2026-06-02

Personalized Neoantigen Vaccines Expand Across Solid Tumors

Today's brief highlights the expanding clinical application of personalized neoantigen vaccines across diverse solid tumors, including melanoma, glioblastoma, and triple-negative breast cancer, often in combination with checkpoint inhibitors.

Concurrently, preclinical research advances delivery platforms, such as cationic liposomes and GFP-like scaffolds, to enhance immunogenicity and stability of neoantigen constructs.

Clinical10

Clinical

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutchinson Cancer Center has launched a Phase I trial recruiting patients with stage IIIC-IV melanoma, metastatic breast cancer, or stage III-IV NSCLC. The study evaluates a personalized neo-antigen peptide vaccine combined with the Th1-polarizing adjuvant poly ICLC to induce polyclonal cytolytic T cell immunity.

clinicaltrials · 2026-03-12 · Fred Hutchinson Cancer Center

Clinical

David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC - Urology Times

David Braun, MD, discusses a Phase 2 trial of an individualized neoantigen therapy for renal cell carcinoma (RCC). This coverage signals ongoing clinical validation of personalized approaches in urologic malignancies beyond melanoma and lung cancer.

news · 2025-02-15 · Urology Times

Clinical

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

The National Cancer Institute (NCI) is conducting a Phase II trial testing the addition of a personalized synthetic long peptide neoantigen vaccine to durvalumab, tremelimumab, and nab-paclitaxel in metastatic triple-negative breast cancer. This aims to determine if adding the vaccine improves outcomes over the standard chemo-immunotherapy backbone.

clinicaltrials · 2026-05-13 · National Cancer Institute (NCI)

Clinical

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine is running a Phase I study of a personalized neoantigen-based DNA vaccine combined with retifanlimab (PD-1 blockade) in newly diagnosed, unmethylated glioblastoma. The trial assesses safety and immunogenicity, targeting a population with limited therapeutic options.

clinicaltrials · 2026-05-04 · Washington University School of Medicine

Clinical

Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery

Beijing Tiantan Hospital completed a Phase I study evaluating autologous dendritic cells loaded with tumor neoantigen peptides alongside temozolomide in newly diagnosed glioblastoma. The trial focused on safety and preliminary efficacy, contributing data on DC-based vaccine platforms in this indication.

clinicaltrials · 2026-05-04 · Beijing Tiantan Hospital

Clinical

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

UNC Lineberger Comprehensive Cancer Center has suspended a Phase I trial of the PANDA-VAC personalized neoantigen peptide vaccine administered concurrently with pembrolizumab. The study was designed for advanced squamous NSCLC and head and neck squamous cell carcinoma, assessing safety and dose adjustment protocols.

clinicaltrials · 2026-04-23 · UNC Lineberger Comprehensive Cancer Center

Clinical

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Dana-Farber Cancer Institute is conducting an active, non-recruiting Phase I study of a personalized neoantigen vaccine combined with rituximab, poly-ICLC, and pembrolizumab for follicular lymphoma. This extends the application of personalized vaccines from solid tumors to hematologic malignancies.

clinicaltrials · 2026-03-25 · Dana-Farber Cancer Institute

Clinical

Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy

A preclinical study maps the immunodominance hierarchy of endogenous neoantigens in the BBN963 bladder cancer model. Using high-throughput ELISpot, researchers found that anti-PD-1 and anti-CTLA-4 therapies do not substantially reshape this hierarchy, suggesting stable antigen targets for vaccine design regardless of checkpoint inhibition status.

biorxiv · 2026-05-27 · Fini, M. S.; Alley, J. R.; Vensko, S. P.; Karthikeyan, D.; Lee, J. S.; Garness, J. A.; Pau

Clinical

Personalized Cancer Vaccine/Pembrolizumab Feasible, Effective in Newly Diagnosed GBM - CancerNetwork

CancerNetwork reports that a personalized cancer vaccine combined with pembrolizumab is feasible and effective in patients with newly diagnosed glioblastoma (GBM). This supports the strategy of pairing neoantigen vaccines with PD-1 blockade in aggressive CNS tumors.

news · 2026-05-31 · CancerNetwork

Clinical

Personalized Cancer Vaccines Show Promise for Select Melanoma Populations - CancerNetwork

Personalized Cancer Vaccines Show Promise for Select Melanoma Populations CancerNetwork

news · 2026-04-08 · CancerNetwork

AI & Methods05

AI / Methods

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms.

A new pipeline utilizes GFP-like protein scaffolds and the mouse nidogen G2 domain for stable, soluble neoantigen display. This modular platform allows for the insertion of tumor-derived peptides without compromising structural integrity, offering a scalable method for next-generation subunit cancer vaccines.

europepmc · 2026-03-25 · Parladé E, Favaro MTP, Chellou-Bakkali S, Voltà-Durán E, López-Laguna H, Villaverde A, Váz

AI / Methods

CIT tumor lines: A series of immunogenic murine cutaneous squamous cell carcinoma cell lines derived from chemical carcinogenesis.

Researchers established 11 syngeneic murine cutaneous squamous cell carcinoma (CIT) tumor lines to model skin cancer immunotherapy. These lines recapitulate human mutational burdens and show varying immune infiltration, with 'hot' lines responding to checkpoint inhibitors, providing a new preclinical platform for neoantigen research in SCC.

europepmc · 2026-04-15 · Letchworth R, Tanaka M, Barnes AA, Lum L, Hughes S, Schlauderaff G, Chaudhary P, Ng KM, Su

AI / Methods

Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control.

Preclinical data demonstrates that cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induce superior tumor control in a murine colorectal cancer model. The liposomal formulation significantly enhanced neoepitope-specific T cell responses compared to soluble peptides, curing 60% of mice with lethal tumors.

europepmc · 2026-04-05 · Spitzer FS, Heuts J, Hos BJ, Romeijn S, Camps MGM, Ossendorp F, van der Maaden K.

AI / Methods

A novel microprotein L3EMP triggers lung adenocarcinoma progression by catalysing the deubiquitination of SIRT1.

A study identifies L3EMP, a microprotein encoded by LINC00973, as a driver of lung adenocarcinoma progression via SIRT1 stabilization. The research highlights L3EMP as a potential neoantigen target, evaluating its immunotherapeutic potential using synthetic peptides and CAR-T cells.

europepmc · 2026-04-06 · Chen Y, Chen Q, Li Q, Guo J, Li Z, Li H, Hu Y, Guo G, Lu L, Li Q, Sun M, Liu X, Nie F.

AI / Methods

Healthy donor T cell receptors expand functional neoantigen recognition beyond patient vaccination - Science | AAAS

A Science publication reports that healthy donor T cell receptors can expand functional neoantigen recognition beyond patient vaccination. This finding suggests potential for off-the-shelf TCR therapies or broader immune monitoring strategies that do not rely solely on patient-specific vaccine responses.

news · 2026-04-17 · Science | AAAS